Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from epithelial cells of the fallopian tube.
Biomarker and diagnostic research for fallopian tube carcinoma has been reported in the published literature.
1 FDA-approved treatment is available for fallopian tube carcinoma, including BEVACIZUMAB (AVASTIN, approved 2004).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
AVASTIN | BEVACIZUMAB | — | 2004 | Available |
171 clinical trials registered, 37 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 21 PHASE3, 66 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05086692](https://clinicaltrials.gov/study/NCT05086692) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
171 trials found
A Beta-only IL-2 ImmunoTherapY Study |
PHASE1 |
Medicenna Therapeutics, Inc. |
RECRUITING |
[NCT05538091](https://clinicaltrials.gov/study/NCT05538091) | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | PHASE2 | Ronald Buckanovich | RECRUITING |
[NCT06735326](https://clinicaltrials.gov/study/NCT06735326) | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | PHASE2 | Qilu Hospital of Shandong University | RECRUITING |
[NCT04055649](https://clinicaltrials.gov/study/NCT04055649) | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | PHASE2 | Ira Winer | RECRUITING |
[NCT06483048](https://clinicaltrials.gov/study/NCT06483048) | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | PHASE1 | Mayo Clinic | RECRUITING |
93 publications have been identified in PubMed for fallopian tube carcinoma. Research spans Case Report / Case Series (27%), Epidemiology / Natural History (24%), and Clinical Trial Publication (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 25 | 27% |
Disease patterns and progression | 22 | 24% |
Clinical study results | 15 | 16% |
Research summaries | 11 | 12% |
Testing and diagnosis research | 8 | 9% |
Laboratory research | 8 | 9% |
Other research | 4 | 4% |
Pence S (2026). [PMID: 42222396](https://pubmed.ncbi.nlm.nih.gov/42222396/). *Front Oncol*. [Clinical Trial Publication]
Li X (2026). [PMID: 41676769](https://pubmed.ncbi.nlm.nih.gov/41676769/). *Hepatobiliary Surg Nutr*. [Other]
Xi X (2026). [PMID: 41491467](https://pubmed.ncbi.nlm.nih.gov/41491467/). *BMC Womens Health*. [Review / Meta-Analysis]
Migdał M (2026). [PMID: 41598536](https://pubmed.ncbi.nlm.nih.gov/41598536/). *J Clin Med*. [Basic Science / Preclinical]
Cheng D (2026). [PMID: 41816664](https://pubmed.ncbi.nlm.nih.gov/41816664/). *Front Med (Lausanne)*. [Case Report / Case Series]
Machuca-Aguado J (2026). [PMID: 40758752](https://pubmed.ncbi.nlm.nih.gov/40758752/). *Int J Gynecol Pathol*. [Case Report / Case Series]
Lien CJ (2026). [PMID: 41758080](https://pubmed.ncbi.nlm.nih.gov/41758080/). *Ann Emerg Med*. [Case Report / Case Series]
Rossouw B (2026). [PMID: 41619087](https://pubmed.ncbi.nlm.nih.gov/41619087/). *Fam Cancer*. [Review / Meta-Analysis]
Landon BV (2026). [PMID: 41652014](https://pubmed.ncbi.nlm.nih.gov/41652014/). *Commun Med (Lond)*. [Clinical Trial Publication]
Shash E (2026). [PMID: 41639797](https://pubmed.ncbi.nlm.nih.gov/41639797/). *BMC Cancer*. [Epidemiology / Natural History]
AI-curated news mentioning fallopian tube carcinoma
Updated Sep 10, 2026
Sapanisertib shows promise for treating rare mTOR-driven disorders, with potential applications in various cancers including bladder and ovarian cancer. Successful late-stage clinical development could unlock orphan-drug incentives and enhance adoption in specialized treatment centers.
A case report details a fallopian tube nontuberculous mycobacterial infection caused by Mycobacterium abscessus, which mimicked fallopian tube carcinoma. This finding highlights the need for differential diagnosis in similar cases.